Get the Stockscreener App
451.23
0.72%
3.22
Pre-market:
452.74
1.51
+0.33%
Vertex Pharmaceuticals Inc stock is traded at $451.23, with a volume of 1.56M.
It is up +0.72% in the last 24 hours and down -6.58% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$448.01
Open:
$448.46
24h Volume:
1.56M
Relative Volume:
1.48
Market Cap:
$115.74B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
33.85
EPS:
13.33
Net Cash Flow:
$-1.35B
1W Performance:
-8.77%
1M Performance:
-6.58%
6M Performance:
+1.20%
1Y Performance:
+26.45%
1-Day Range:
$445.38
$451.76
1-Week Range:
$445.38
$496.33
52-Week Range:
$346.29
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
PNC Financial Services Group Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded to "Buy" Rating by StockNews.com - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Lifted by Advisors Asset Management Inc. - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Portfolio Design Labs LLC - MarketBeat
EULAV Asset Management Has $14.65 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Trimmed by MWA Asset Management - MarketBeat
57,825 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Segall Bryant & Hamill LLC - MarketBeat
Northwest Bancshares Inc. Has $6.10 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Strategy Asset Managers LLC Sells 1,805 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Pathstone Holdings LLC Purchases 2,112 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Quest Partners LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by W.G. Shaheen & Associates DBA Whitney & Co - MarketBeat
1,424 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Whalen Wealth Management Inc. - MarketBeat
First Turn Management LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Thrivent Financial for Lutherans Sells 3,119 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by OneDigital Investment Advisors LLC - MarketBeat
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Swiss National Bank - MarketBeat
Atlanta Consulting Group Advisors LLC Purchases 1,331 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Empowered Funds LLC Sells 17,482 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Natixis Advisors LLC - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Lifted by Mizuho Securities USA LLC - MarketBeat
Kentucky Retirement Systems Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CIBC Asset Management Inc Acquires 4,432 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Impax Asset Management Group plc Has $3.46 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Broderick Brian C Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Huntington National Bank - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by Citigroup - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Increased by KBC Group NV - MarketBeat
Citigroup Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Buy Recommendation - MSN
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Vertex Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Benchmark - MSN
Sivik Global Healthcare LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aubrey Capital Management Ltd Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Pinnacle Financial Partners Inc Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain - STAT
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline tests - Investing.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP & CFO C - GuruFocus.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Chase Investment Counsel Corp Has $3.28 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Victory Capital Management Inc. Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aptus Capital Advisors LLC Buys 3,071 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Baillie Gifford & Co. Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
WealthPlan Investment Management LLC Takes $635,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):